Evidence map›Paper›PMID 27189522›Full record

ArticleExperimental and molecular pathology2016

Mitigation of nitrogen mustard mediated skin injury by a novel indomethacin bifunctional prodrug.

Gabriella M Composto, Jeffrey D Laskin, Debra L Laskin, Donald R Gerecke, Robert P Casillas, Ned D Heindel, Laurie B Joseph, Diane E Heck

Open access · greenAbstract read
In one paragraph

Article in Experimental and molecular pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Buprenorphine blunts inflammatory response and wound progression after skin exposure to nitrogen mustard.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gabriella M CompostoDepartment of Pharmacology and Toxicology, Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ, United States.
Jeffrey D LaskinDepartment of Environmental and Occupational Health, Rutgers University School of Public Health, Piscataway, NJ, United States.
Debra L LaskinDepartment of Pharmacology and Toxicology, Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ, United States.
Donald R GereckeDepartment of Pharmacology and Toxicology, Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ, United States.
Robert P CasillasMRIGlobal, Kansas City, MO, United States.
Ned D HeindelDepartment of Chemistry, Lehigh University, Bethlehem, PA, United States.
Laurie B JosephDepartment of Pharmacology and Toxicology, Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ, United States.
Diane E HeckDepartment of Environmental Health Science, New York Medical College, Valhalla, NY, United States. Electronic address: Diane_Heck@nymc.edu.
Rutgers, The State University of New Jersey · USLehigh University · USMRIGlobal · USNew York Medical College · US

Funding

UMDNJ/Rutgers University CounterACT Research Center of ExcellenceU54AR055073 · NIAMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI HECK, DIANE E · 2006 to 2024
$71.4M
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
TRAINING IN EVIRONMENTAL TOXICOLOGYT32ES007148 · NIEHS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI Lauren M Aleksunes · 1987 to 2026
$11.4M
ACTIVATED MACROPHAGES AND OZONE TOXICITYR01ES004738 · NIEHS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI Debra L Laskin · 1989 to 2026
$9.0M
Developing Drugs to Mitigate Parathion IntoxicationU01NS079249 · NINDS · RBHS-SCHOOL OF PUBLIC HEALTH · PI LASKIN, JEFFREY D, RICHARDSON, JASON R · 2013 to 2017
$4.0M
NIAMS NIH HHS U54 AR055073NIEHS NIH HHS P30 ES005022NIEHS NIH HHS R01 ES004738NIEHS NIH HHS T32 ES007148NINDS NIH HHS U01 NS079249
6 · The paper itself

Abstract

Nitrogen mustard (NM) is a bifunctional alkylating agent that is highly reactive in the skin causing extensive tissue damage and blistering. In the present studies, a modified cutaneous murine patch model was developed to characterize NM-induced injury and to evaluate the efficacy of an indomethacin pro-drug in mitigating toxicity. NM (20μmol) or vehicle control was applied onto 6mm glass microfiber filters affixed to the shaved dorsal skin of CD-1 mice for 6min. This resulted in absorption of approximately 4μmol of NM. NM caused localized skin damage within 1 d, progressing to an eschar within 2-3 d, followed by wound healing after 4-5 d. NM-induced injury was associated with increases in skin thickness, inflammatory cell infiltration, reduced numbers of sebocytes, basal keratinocyte double stranded DNA breaks, as measured by phospho-histone 2A.X expression, mast cell degranulation and increases in inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Wound healing was characterized by epidermal hyperplasia and marked increases in basal cells expressing proliferating cell nuclear antigen. A novel indomethacin-anticholinergic prodrug (4338) designed to target cyclooxygenases and acetylcholinesterase (AChE), was found to markedly suppress NM toxicity, decreasing wound thickness and eschar formation. The prodrug also inhibited mast cell degranulation, suppressed keratinocyte expression of iNOS and COX-2, as well as markers of epidermal proliferation. These findings indicate that a novel bifunctional pro-drug is effective in limiting NM mediated dermal injury. Moreover, our newly developed cutaneous patch model is a sensitive and reproducible method to assess the mechanism of action of countermeasures.

Indexed as

Alkylating AgentsAnimalsAnti-Inflammatory AgentsCholinergic AntagonistsCyclooxygenase 2Cyclooxygenase InhibitorsDNA DamageFemaleHistonesImmunohistochemistryIndomethacinKeratinocytesMechlorethamineMiceNitric Oxide Synthase Type IIProdrugs4338 compoundAlkylating AgentsAnti-Inflammatory AgentsCholinergic AntagonistsCyclooxygenase 2Cyclooxygenase Inhibitorsgamma-H2AX protein, mouseHistonesIndomethacinMechlorethamineNitric Oxide Synthase Type IIProdrugsProliferating Cell Nuclear AntigenAnti-cholinergicCountermeasuresEpidermisSulfur mustardVesicants

Identifiers

PMID27189522
PMCPMC4947376
OpenAlexW2387165602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.